Questions about AstraZeneca jab linger | The Business Standard
Skip to main content
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
The Business Standard

Thursday
June 12, 2025

Sign In
Subscribe
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
THURSDAY, JUNE 12, 2025
Questions about AstraZeneca jab linger

Coronavirus chronicle

BSS/AFP
05 April, 2021, 01:00 pm
Last modified: 05 April, 2021, 01:07 pm

Related News

  • France donates 2.12 million more AstraZeneca shots to Bangladesh
  • AstraZeneca therapy works against omicron; results mixed for Regeneron
  • Bangladesh gets over 8m AstraZeneca jabs from Japan, UK
  • Bangladesh gets over 4m Oxford-AstraZeneca jabs from UK
  • Norway, Sweden and Switzerland provide 1.2mn vaccine doses to Bangladesh

Questions about AstraZeneca jab linger

The European Medicines Agency — which has said that benefits outweigh risks such that the vaccine should remain in use — will provide an updated assessment next week

BSS/AFP
05 April, 2021, 01:00 pm
Last modified: 05 April, 2021, 01:07 pm
A healthcare worker shows a vial and a box of the AstraZeneca coronavirus disease (COVID-19) vaccine, as vaccinations resume after a brief pause in their use over concern for possible connection to blood clots, in Turin, Italy, March 19, 2021. REUTERS/Massimo Pinca
A healthcare worker shows a vial and a box of the AstraZeneca coronavirus disease (COVID-19) vaccine, as vaccinations resume after a brief pause in their use over concern for possible connection to blood clots, in Turin, Italy, March 19, 2021. REUTERS/Massimo Pinca

Persistent questions on whether rare but serious blood clots among those getting the AstraZeneca jab against Covid-19 are more frequent than in the general population, and what causes them if they are, have continued to undermine confidence in the beleaguered vaccine.

The European Medicines Agency — which has said that benefits outweigh risks such that the vaccine should remain in use — will provide an updated assessment next week.

What Has Been Observed?

The Business Standard Google News Keep updated, follow The Business Standard's Google news channel

The blood clots seen in a handful of people vaccinated with AstraZeneca are described by the French Medicines Agency (ANSM) as "highly untypical".

"This thrombosis of large veins is unusually located in the brain, and even more rarely in the digestive tract," the agency commented.

It is also associated with a condition characterised by abnormally low levels of platelets, which are small cell fragments in our blood that form clots to stop or prevent bleeding.

In mid-March Germany's medicines regulator, the Paul Ehrlich Institute (PEI), was the first national health authority to flag what they described as an aberrantly high number of cases involving these rare cerebral blood clots, mostly in younger and middle-aged women.

According to some specialists, this set of symptoms pointed to so-called disseminated intravascular coagulation (DIC), in which blood clots form throughout the body.

Also seen in extreme cases of sepsis, this condition involves "both thrombosis and haemorrhaging", Odile Launay, a member of the scientific body advising the French government on Covid-19 vaccines, told AFP.

Link With The Vaccine?

"A causal link with the vaccine is not proven but is possible, and further analysis is continuing," the EMA said last week.

The agency is scheduled to meet on the question from April 6-9. Other specialists were more categorical.

"We have to stop speculating on whether there is a link or not — all the cases showed these symptoms three to 10 days after inoculation with the AstraZeneca vaccine," Pal Andre Holme, who heads a team at Oslo National Hospital working on these cases, told Norwegian television.

"We have not found any other triggering factor."

Norway's national medicines agency backed this assessment, with one of their executives, Steinar Madsen, saying "there is probably a link with the vaccine".

For its part, France's ANSM — pointing to "the very unusual type of thrombosis, a similar clinical profile, and similar timing of onset" — said there was a "small" risk.

How Big Is The Risk?

As of March 31, the EMA identified 62 cases of cerebral venous sinus thrombosis (CVST) in the world — 44 of them in Europe — among 9.2 million doses of AstraZeneca administered.

Of those, 14 have resulted in death, though it is not possible to definitively attribute fatalities to this rare form of thrombosis, the head of the EMA, Emer Cooke, said last week in a videoconference.

The statistics, she added, are comprehensive, or close to it.

In Germany, there have been 31 suspected cases of CVST — 19 accompanied by a drop in blood platelets — with nine deaths, according to the Paul-Ehrlich Institute.

These cases were spread across 2.8 million AstraZeneca vaccine doses injected, or just over one case per 100,000 doses.

The comparable figures for France are 12 cases and four deaths out of 1.9 million doses, and for Norway, five cases and three deaths out of 120,000 doses.

Britain — where AstraZeneca has been administered more than in any other country — registered 30 cases as of Saturday, including seven fatalities, across a total of 18.1 million doses.

But as is true of all medications, risks must always be weighed against benefits.

"We would all prefer to have drugs that are 100 percent safe but they don't exist," Adam Finn, a professor of paediatrics at University of Bristol, told the London-based Science Media Centre last week, commenting on renewed bans of the AstraZeneca vaccine in Germany and elsewhere.

"Right now the biggest risk to our lives and livelihoods throughout the world is Covid-19," Finn added. "We need to stay focussed on the need to prevent it taking millions more human lives before it is brought under control and the only effective way to do that is through vaccination."

The EMA has consistently echoed this view.

"The benefits of the AstraZeneca vaccine in preventing Covid-19, with its associated risk of hospitalisation and death, outweigh the risks of side effects," it said in statement on March 31. – Risk factors?

Most cases of cerebral thrombosis have occurred in those under 65, but it is impossible to draw any conclusions about age because the vaccine has been administered to date mostly among younger populations.

The fact that a majority of cases have been among women may simply reflect the fact the health sector — predominately women — was given priority for vaccination.

"At present the review has not identified any specific risk factors, such as age, gender or a previous medical history of clotting disorders for these very rare events," the EMA said.

Notwithstanding, after some countries temporarily paused the AstraZeneca jab in mid-March, several countries have now suspended the vaccine again.

Germany decided last week to ban its use for anyone under 60, while in Canada — as in France — the age threshold is 55. In Sweden the age cutoff is 65.

"We do not have just one vaccine, we have several," Sandra Ciesek, a professor of medical virology at the Goethe University Frankfurt, wrote in Science magazine.

"So, restricting the AstraZeneca vaccine to older people makes sense to me."

Norway and Sweden have taken the more radical step of suspending the AstraZeneca vaccine altogether.

Possible Explanations?

For the moment, there are only hypotheses, though the EMA is expected to suggest next week which are the more likely.

In a study released on March 28 that has not yet been peer-reviewed, German and Austrian researchers pointed to a known biological mechanism as a possible explanation for the apparent surge in atypical thrombosis.

The AstraZeneca vaccine, they wrote, is associated with a thrombosis disorder "that clinically resembles heparin-induced thrombocytopenia (HIT)".

HIT is a rare and serious reaction of the immune system to the anti- coagulant medication heparin.

The authors, led by Andreas Greinacher from the University of Greifswald, proposed a name for what they described as a new syndrome: "vaccine-induced prothrombotic immune thrombocytopenia (VIPIT)."

Researchers at Oslo National Hospital had earlier suggested that cases might have been triggered by a "powerful immune response" to the vaccine.

An association of French scientists and doctors called "On the Side of Science" have said such an immune response could come from the accidental insertion of the needle into a vein in the upper arm, rather than muscle.

Top News

AstraZeneca Covid-19 Vaccine / AstraZeneca Plc / AstraZeneca vaccine / Oxford-AstraZeneca / Oxford-AstraZeneca vaccine

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Saifuzzaman Chowdhury. Photo: Collected
    UK crime agency now freezes assets of ex-land minister Saifuzzaman: AJ
  • Chief Adviser Muhammad Yunus speaks at the Chatham House in London on 11 June 2025. Photo: CA Press Wing
    No desire to be part of next elected govt: CA Yunus
  • File photo of BNP Standing Committee Member Amir Khasru Mahmud Chowdhury. Photo: Collected
    Khasru flies to London ahead of Yunus-Tarique meeting

MOST VIEWED

  • Illustration: Duniya Jahan/ TBS
    Forget Katy Perry, here’s Bangladesh’s Ruthba Yasmin shooting for the moon
  • A file photo of Bangladesh Bank Governor Dr Ahsan H Mansur. Photo: Collected
    'I have no relation with this': Ahsan Mansur debunks Joy’s allegations over daughter’s Dubai flat
  • Faiz Ahmad Tayeb. Photo: BSS
    Import duty on raw materials for e-bikes, lithium batteries reduced from 80% to 1% in some cases: Faiz Taiyeb
  • File photo of ex-prime minister Sheikh Hasina and her son Sajeeb Wazed Joy. Photo: Collected
    Joy spends Eid with Hasina in India: Indian media
  • Mercantile Bank withholds dividend amid Tk1,700cr provision shortfall
    Mercantile Bank withholds dividend amid Tk1,700cr provision shortfall
  • Shakil Ahmed. Photo: Collected
    DU student allegedly hangs himself following threats over old derogatory comment about Prophet on Facebook

Related News

  • France donates 2.12 million more AstraZeneca shots to Bangladesh
  • AstraZeneca therapy works against omicron; results mixed for Regeneron
  • Bangladesh gets over 8m AstraZeneca jabs from Japan, UK
  • Bangladesh gets over 4m Oxford-AstraZeneca jabs from UK
  • Norway, Sweden and Switzerland provide 1.2mn vaccine doses to Bangladesh

Features

Among pet birds in the country, lovebirds are the most common, and they are also the most numerous in the haat. Photo: Junayet Rashel

Where feathers meet fortune: How a small pigeon stall became Dhaka’s premiere bird market

10h | Panorama
Illustration: Duniya Jahan/ TBS

Forget Katy Perry, here’s Bangladesh’s Ruthba Yasmin shooting for the moon

1d | Features
File photo of Eid holidaymakers returning to the capital from their country homes/Rajib Dhar

Dhaka: The city we never want to return to, but always do

2d | Features
Photo collage shows political posters in Bagerhat. Photos: Jannatul Naym Pieal

From Sheikh Dynasty to sibling rivalry: Bagerhat signals a turning tide in local politics

4d | Bangladesh

More Videos from TBS

Why is Omicron XBB more contagious?

Why is Omicron XBB more contagious?

6h | TBS Stories
What did Dr. Yunus say at the Chatham House Dialogue in London?

What did Dr. Yunus say at the Chatham House Dialogue in London?

7h | TBS Today
News of The Day, 11 JUNE 2025

News of The Day, 11 JUNE 2025

8h | TBS News of the day
WB predicts worst decade for global growth since 60s

WB predicts worst decade for global growth since 60s

10h | TBS Stories
EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Advertisement
  • Privacy Policy
  • Comment Policy
Copyright © 2025
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net